Assembly Biosciences (ASMB) Posts Earnings Results, Beats Expectations By $0.14 EPS

Share on StockTwits

Assembly Biosciences (NASDAQ:ASMB) released its earnings results on Thursday. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.14, MarketWatch Earnings reports. The business had revenue of $4.29 million for the quarter, compared to the consensus estimate of $3.21 million. Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%.

Shares of Assembly Biosciences stock traded down $2.19 during trading on Friday, hitting $23.40. The stock had a trading volume of 193,657 shares, compared to its average volume of 168,602. The company has a market cap of $585.27 million, a P/E ratio of -9.71 and a beta of 1.43. Assembly Biosciences has a 1 year low of $20.61 and a 1 year high of $67.36.

Several research analysts have recently weighed in on the stock. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 3rd. Chardan Capital reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Sunday, October 28th. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Monday, October 8th. Finally, ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $62.60.

In other news, VP Uri A. Lopatin sold 15,204 shares of Assembly Biosciences stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $40.09, for a total value of $609,528.36. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 18.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Assembly Biosciences (ASMB) Posts Earnings Results, Beats Expectations By $0.14 EPS” was first published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/11/10/assembly-biosciences-asmb-posts-earnings-results-beats-expectations-by-0-14-eps/2972487.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

See Also: How to Use the New Google Finance Tool

Earnings History for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.